The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Open accessPublished version of a preprint
Abstract
Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) after pembrolizumab treatment in melanoma patients. Experimental Design: Serum lactate dehydrogenase (LDH), routine blood count parameters, and clinical characteristics were investigated in 616 patients. Endpoints were OS and best overall response following pembrolizumab treatment. Kaplan–Meier analysis and Cox regression were applied for survival analysis. Results: Relative eosinophil count (REC) ≥1.5%, relative lymphocyte count (RLC) ≥17.5%, ≤2.5-fold elevation of LDH, and the absence of metastasis other than soft-tissue/lung were associated with favorable OS in the discovery (n = 177) and the confirmation (n = 182) cohort and had independent positive impact (all P < 0.001). Their independent role was subsequently confirmed in the validation cohort (n = 257; all P < 0.01). The number of favorable factors was strongly associated with prognosis. One-year OS probabilities of 83.9% versus 14.7% and response rates of 58.3% versus 3.3% were observed in patients with four of four compared to those with none of four favorable baseline factors present, respectively. Conclusions: High REC and RLC, low LDH, and absence of metastasis other than soft-tissue/lung are independent baseline characteristics associated with favorable OS of patients with melanoma treated with pembrolizumab. Presence of four favorable factors in combination identifies a subgroup with excellent prognosis. In contrast, patients with no favorable factors present have a poor prognosis, despite pembrolizumab, and additional treatment advances are still needed. A potential predictive impact needs to be further investigated. Clin Cancer Res; 22(22); 5487–96. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, an elevated eosinophil count prior to treatment was associated with longer overall survival in several studies.8–12”
In the citing paper
“Other pre-treatment immunological factors associated with improved treatment responses include high eosinophil and lymphocyte blood counts, an abundance of CD8+ T cells infiltrating the tumor or present at the tumor margin, and increased serum TGF-β levels in melanoma patients treated with anti-PD-1 (88, 91, 92, 109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [109]
In the citing paper
“Importantly, it has been shown that investigating several biomarkers in combination can improve treatment predictions (109).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Blocking antibodies targeting PD-1 or its counterpart PD-L1 can prevent this form of T cell inactivation (1, 10, 18, 34) ensuring sustained antitumor activity.”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Cited by
Sorted by citations
Items 301–400 of 585
Gearing up T-cell immunotherapy in cervical cancer
Chauhan, S. R., & Bharadwaj, M. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.04.001 · Cited by 20
Atallah‐Yunes, S. A., Kadado, A. J., & Soe, M. H. (2019) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2019.01.001 · Cited by 20
Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy
Khan, T., Nagarajan, M. K., Kang, I., Wu, C., & Wangpaichitr, M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15020050 · Cited by 21
Sibille, A., Henket, M. A., Corhay, J. L., Alfieri, R., Louis, R. E., & Duysinx, B. (2021) · Lung · doi:10.1007/s00408-021-00474-2 · Cited by 19
Wendlinger, S., Wohlfarth, J., Kreft, S., Siedel, C., Kilian, T., Dischinger, U., Heppt, M. V., Wistuba‐Hamprecht, K., Meier, F. E., Goebeler, M., et al. (2022) · Cancers · doi:10.3390/cancers14092294 · Cited by 19
Self-citationCui, C., Chen, Y., Luo, Z., Zou, Z., Jiang, Y., Pan, H., Fan, Q., Zhao, J., Xu, Q., Jiang, R., et al. (2023) · BMC Cancer · doi:10.1186/s12885-022-10473-y · Cited by 19
Perspectives for immunotherapy in endocrine cancer
Latteyer, S., Tiedje, V., Schilling, B., & Führer, D. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0169 · Cited by 20
Self-citationPembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
Song, H., Kang, M. G., Park, J. R., Hwang, J., Kang, J. H., Lee, W. S., & Lee, G. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.529 · Cited by 19
Established, emerging and elusive molecular targets in the treatment of lung cancer
Gallant, J., & Lovly, C. M. (2018) · The Journal of Pathology · doi:10.1002/path.5038 · Cited by 22
Stepula, E., König, M., Wang, X., Levermann, J., Schimming, T. T., Kasimir‐Bauer, S., Schilling, B., & Schlücker, S. (2019) · Journal of Biophotonics · doi:10.1002/jbio.201960034 · Cited by 19
Self-citationZhao, X., Kong, Y., & Zhang, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01625 · Cited by 19
Bai, R., Li, L., Chen, X., Chen, N., Song, W., Zhang, Y., Lv, Z., Han, F., Zhao, Y., Li, W., et al. (2021) · Journal of Oncology · doi:10.1155/2021/9935076 · Cited by 19
Placke, J., Soun, C., Bottek, J., Herbst, R. A., Terheyden, P. A. M., Utikal, J. S., Pföhler, C., Ulrich, J., Kreuter, A., Pfeiffer, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741993 · Cited by 20
Self-citationBiomarkers for Checkpoint Inhibition
Weber, J. S. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175463 · Cited by 18
Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy
Strudel, M., Festino, L., Vanella, V., Beretta, M., Marincola, F. M., & Ascierto, P. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191205160007 · Cited by 18
Self-citationOvercoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
García‐Sancha, N., Corchado‐Cobos, R., Bellido-Hernández, L., Román‐Curto, C., Álvarez, E. C., Pérez‐Losada, J., Órfão, A., & Cañueto, J. (2021) · Cancers · doi:10.3390/cancers13205134 · Cited by 21
Haist, M., Stege, H. M., Ebner, R., Fleischer, M. I., Loquai, C., & Grabbe, S. (2022) · Cancers · doi:10.3390/cancers14092082 · Cited by 18
Mehra, T., Dongre, K., Boesing, M., Frei, P., Suenderhauf, C., Zippelius, A., Leuppi, J. D., WICKI, A. N., & Leuppi-Taegtmeyer, A. B. (2023) · Cancer Medicine · doi:10.1002/cam4.5919 · Cited by 18
Insight into Cancer Immunity: MHCs, Immune Cells and Commensal Microbiota
Wen, M., Li, Y., Qin, X., Qin, B., & Wang, Q. A. (2023) · Cells · doi:10.3390/cells12141882 · Cited by 20
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
Tunger, A., Kießler, M., Wehner, R., Temme, A., Meier, F. E., Bachmann, M. P., & Schmitz, M. (2018) · Biomedicines · doi:10.3390/biomedicines6010026 · Cited by 18
Self-citationNivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma
Suzuki, K., Terakawa, T., Furukawa, J., Harada, K., Hinata, N., Nakano, Y., & Fujisawa, M. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000299 · Cited by 18
‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors
Gunjur, A., Manrique-Rincón, A., Klein, O., Behren, A., Lawley, T. D., Welsh, S. J., & Adams, D. J. (2022) · The Journal of Pathology · doi:10.1002/path.5907 · Cited by 18
Biomarkers of Hyperprogression and Pseudoprogression with Immune Checkpoint Inhibitor Therapy
Failing, J. J., Dudek, O. A., Marin-Acevedo, J. A., Chirilă, R. M., Dong, H., Markovic, S. N., & Dronca, R. S. (2019) · Future Oncology · doi:10.2217/fon-2019-0183 · Cited by 18
Zhang, X., Zhang, B., Li, D., Yang, Y., Lin, S., Zhao, R., Li, Y., & Peng, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1528084 · Cited by 18
Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report
Occhipinti, M. A., Falcone, R., Onesti, C. E., & Marchetti, P. (2018) · Drug Safety - Case Reports · doi:10.1007/s40800-018-0078-z · Cited by 17
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Tsur, N., Kogan, Y., Avizov-Khodak, E., Vaeth, D., Vogler, N., Utikal, J. S., Lotem, M., & Agur, Z. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2081-2 · Cited by 17
Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer
Wistuba‐Hamprecht, K., Gouttefangeas, C., Weide, B., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01152 · Cited by 17
Self-citationCybulska-Stopa, B., Rogala, P., Czarnecka, A. M., Lugowska, I. A., Teterycz, P., Galus, Ł., Rajczykowski, M., Dawidowska, A., Piejko, K., Suwiński, R., et al. (2020) · Advances in Medical Sciences · doi:10.1016/j.advms.2020.05.005 · Cited by 17
Strippoli, S., Fanizzi, A., Negri, A., Quaresmini, D., Nardone, A., Armenio, A., Sciacovelli, A. M., Massafra, R., Risi, I. D., Tullio, G. D., et al. (2021) · Cells · doi:10.3390/cells10020406 · Cited by 17
Gaißler, A., Bochem, J., Spreuer, J., Ottmann, S., Martens, A., Amaral, T. M. S., Wagner, N. B., Claassen, M., Meier, F. E., Terheyden, P. A. M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006802 · Cited by 17
Self-citationQin, A., Street, L., Cease, K. B., Viglianti, B. L., Warren, E. H., Zhao, L., & Ramnath, N. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.01.012 · Cited by 17
Predictive Biomarkers in Cancer Immunotherapy: A Narrative Review Across Selected Solid Tumors
Puntambekar, M., Shery, N., Parokkaran, I. P., & Al-Hamas, M. (2025) · Cureus · doi:10.7759/cureus.88647 · Cited by 17
Promising and Minimally Invasive Biomarkers: Targeting Melanoma
Spiliopoulou, P., Lopes, C. D. H., & Spreafico, A. (2023) · Cells · doi:10.3390/cells13010019 · Cited by 16
Next-Generation Sequencing to Guide Treatment of Advanced Melanoma
Griewank, K., & Schilling, B. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0260-6 · Cited by 17
Self-citationHribernik, N., Boc, M., Ocvirk, J., Knez-Arbeiter, J., Mesti, T., Ignjatović, M. G., & Reberšek, M. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0003 · Cited by 18
Fischer, G. M., Carapeto, F. C. L., Joon, A. Y., Haydu, L. E., Chen, H., Wang, F., Arnam, J. S. V., McQuade, J. L., Wani, K., Kirkwood, J. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3474 · Cited by 16
Costantini, S., Madonna, G., Capone, M., Gennaro, E. D., Bagnara, P., Renza, F., Mallardo, D., Affatato, R., Vitagliano, C., Romanelli, M., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03378-8 · Cited by 15
Self-citationTakeuchi, E., Okano, Y., Machida, H., Atagi, K., Kondou, Y., Kadota, N., Hatakeyama, N., Naruse, K., & Shinohara, T. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02994-5 · Cited by 15
Finon, A., Zaragoza, J., Maillard, H., Bénéton, N., Bens, G., Samimi, M., Caille, A., & Machet, L. (2018) · European Journal of Dermatology · doi:10.1684/ejd.2017.3167 · Cited by 15
Prognostic role of disease extent and lymphocyte–monocyte ratio in advanced melanoma
Iacono, D., Basile, D., Gerratana, L., Vitale, M. G., Pelizzari, G., Cinausero, M., Poletto, E., Puglisi, F., Fasola, G., & Minisini, A. M. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000584 · Cited by 15
Prognostic Biomarkers for Melanoma Immunotherapy
Twitty, C., Huppert, L. A., & DAUD, A. I. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0886-z · Cited by 15
Zhao, J., Wen, X., Ding, Y., Li, D., Zhu, B., Li, J., Weng, D., Zhang, X., & Zhang, X. (2020) · Aging · doi:10.18632/aging.103285 · Cited by 15
Pan, M., Alavi, M., & Herrinton, L. J. (2018) · The Permanente Journal · doi:10.7812/tpp/17-149 · Cited by 15
Reijers, I. L. M., Rozeman, E. A., Wilgenhof, S., van Thienen, J. V., Haanen, J. B. A. G., & Blank, C. U. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12835 · Cited by 15
Self-citationWagner, N. B., Luttermann, F., Gassenmaier, M., Forschner, A., Leiter, U., Garbe, C., & Eigentler, T. (2020) · Australasian Journal of Dermatology · doi:10.1111/ajd.13248 · Cited by 15
Self-citationOhashi, H., Takeuchi, S., Miyagaki, T., & Kadono, T. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.03043 · Cited by 15
Rafei-Shamsabadi, D. A., Lehr, S., Behrens, M., & Meiß, F. (2022) · Cancers · doi:10.3390/cancers14030540 · Cited by 14
PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
Cristinziano, L., Modestino, L., Capone, M., Madonna, G., Mallardo, D., Giannarelli, D., D’Angelo, G., Ferrara, A. L., Loffredo, S., Varricchi, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962669 · Cited by 14
Self-citationTawbi, H. A., To, T. M., Bartley, K., Sadetsky, N., Burton, E. M., Haydu, L. E., & Mckenna, E. F. (2021) · Cancer Medicine · doi:10.1002/cam4.4438 · Cited by 14
Hino, C., Nishino, K., Pham, B., Jeon, W. J., Nguyen, M., & Cao, H. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993622 · Cited by 14
Immune checkpoint molecules in prevention and development of asthma
Kanannejad, Z., Soleimanian, S., Ghahramani, Z., Sepahi, N., Mohkam, M., Alyasin, S. S., & Kheshtchin, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1070779 · Cited by 14
Johnson, L. E., Olson, B. M., & McNeel, D. G. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0260-3 · Cited by 14
Predictors of response and resistance to checkpoint inhibitors in solid tumors
Rao, S., Moran, A. E., & Graff, J. N. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.09.35 · Cited by 14
Wagner, N. B., Lenders, M. M., Kühl, K., Reinhardt, L., André, F., Dudda, M., Ring, N., Ebel, C., Staeger, R., Zellweger, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002350 · Cited by 13
Self-citationWang, Z., Liu, C. X., Bai, Y., Zhao, X., Cui, L., Peng, Z., Zhang, X., Wang, X., Zhao, Z., Li, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.761110 · Cited by 13
Li, L., Zhu, R., Zhou, H., Cui, C., Xiao, Y., Liu, Y., Yin, Y., Li, Y., Feng, R., Katz, J. P., et al. (2023) · Advanced Science · doi:10.1002/advs.202207458 · Cited by 13
Chadokiya, J., Chang, K., Sharma, S., Hu, J., Lill, J. R., Dionne, J. A., & Kirane, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1520860 · Cited by 13
Omero, F., Speranza, D., Murdaca, G., Cavaleri, M., Marafioti, M., Cianci, V., Berretta, M., Casciaro, M., Gangemi, S., & Santarpía, M. (2025) · Biomolecules · doi:10.3390/biom15040491 · Cited by 13
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
Pezeshki, P. S., Sharif, P. M., & Rezaei, N. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1929919 · Cited by 13
Daher, S., Lawrence, Y. R., Dudnik, E., Hanovich, E., Urban, D., Peled, N., Navon, R., Leibowitz‐Amit, R., Hammerman, A., Battat, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.625668 · Cited by 13
Furubayashi, N., Minato, A., Negishi, T., Sakamoto, N., Song, Y., Hori, Y., Tomoda, T., Harada, M., Tamura, S., Miura, A., et al. (2022) · Cancer Management and Research · doi:10.2147/cmar.s360473 · Cited by 13
Ungan, G., Lavandier, A.-F., Rouanet, J., Hordonneau, C., Chauveau, B., Pereira, B., Boyer, L., Garcier, J., Mansard, S., Bartoli, A., et al. (2022) · International Journal of Computer Assisted Radiology and Surgery · doi:10.1007/s11548-022-02662-8 · Cited by 14
Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
Galati, D., Zanotta, S., Capone, M., Madonna, G., Mallardo, D., Romanelli, M., Simeone, E., Festino, L., Sparano, F., Azzaro, R., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04184-6 · Cited by 13
Self-citationPembrolizumab use for the treatment of advanced melanoma
Specenier, P. M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1309388 · Cited by 13
Voutsadakis, I. A. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.03.03 · Cited by 13
Hiltbrunner, S., Spohn, M.-L., Wechsler, R., Akhoundova, D., Bankel, L., Kasser, S., Bihr, S., Britschgi, C., Maathuis, M. H., & Fontecedro, A. C. (2021) · Cancers · doi:10.3390/cancers14010075 · Cited by 12
Gambale, E., Maruzzo, M., Messina, C. G. M., Aquino, I. D. G., Vascotto, I. A., Rossi, V., Bimbatti, D., Cavasin, N., Messina, M., Mennitto, A., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102099 · Cited by 12
Cocorocchio, E., Martinoli, C., Gandini, S., Pala, L., Conforti, F., Stucchi, S., Mazzarol, G., & Ferrucci, P. F. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02320-y · Cited by 12
Ke, L., Wang, L., Yu, J., & Meng, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.652312 · Cited by 12
Lim, S. Y., & Rizos, H. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9757-4 · Cited by 12
Deckers, E. A., Wevers, K. P., Kobold, A. C. M., Damude, S., Vrielink, O. M., van Ginkel, R. J., Been, L. B., van Leeuwen, B. L., Hoekstra, H. J., & Kruijff, S. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25682 · Cited by 12
Maio, M., Coukos, G., Ferrone, S., Fox, B. A., Fridman, W. H., Garcia, P. L., Lahn, M., Provendier, O., Russo, V., Rüttinger, D., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2285-y · Cited by 12
Self-citationValidation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma
Syeda, M. M., Wiggins, J. M., Corless, B. C., Spittle, C., Karlin-Neumann, G. A., & Polsky, D. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_7 · Cited by 12
Indini, A., Guardo, L. D., Cimminiello, C., de Braud, F., & Vecchio, M. D. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000566 · Cited by 11
Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1
James, J. L., & Balko, J. M. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00331-5 · Cited by 11
Garg†, S. K., Welsh, E. A., Fang, B., Hernandez, Y., Rose, T. A., Gray, J. E., Koomen, J. M., Berglund, A., Mulé, J. J., & Markowitz, J. (2020) · Cancers · doi:10.3390/cancers12123515 · Cited by 11
Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
Rogers, C. B. B., Zawislak, M. C., & Victoria Wong, P.-C. (2021) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2021.12.4.4 · Cited by 11
Guo, Y., Pan, Y., Wan, J., Gong, B., Li, Y., Kan, X., & Zheng, C. (2024) · BMC Cancer · doi:10.1186/s12885-024-12271-0 · Cited by 10
Li, X., Song, Z., Chen, Y., Wu, J., Jiang, D. L., Zhang, Z., Wang, Z., & Zhao, R. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03816-0 · Cited by 10
Fujimura, T., Tanita, K., Ohuchi, K., Sato, Y., Lyu, C., Kambayashi, Y., Fujisawa, Y., Tanaka, R., Hashimoto, A., & Aiba, S. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000685 · Cited by 10
Clinical Efficacy of Immune Checkpoint Inhibitors in Patients with Brain Metastases
Nunno, V. D., Nuvola, G., Mosca, M., Maggio, I., Gatto, L., Tosoni, A., Lodi, R., Franceschi, E., & Brandes, A. A. (2021) · Immunotherapy · doi:10.2217/imt-2020-0208 · Cited by 10
Suzuki, S., Abe, T., Endo, T., Kaya, H., Kitabayashi, T., Kawasaki, Y., & Yamada, T. (2022) · Cancer Management and Research · doi:10.2147/cmar.s382771 · Cited by 10
Wang, Z., Zou, X., Wang, H., Hao, Z., Li, G., & Wang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1454720 · Cited by 9
Melzer, Y. F., Fergen, N. L., Meß, C., Stadler, J.-C., Geidel, G., Schwietzer, Y. A., Kött, J., Pantel, K., Schneider, S. W., Utikal, J. S., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102224 · Cited by 9
Self-citationJin, X., Zhao, W., Li, G., & Jiang, J. (2025) · Cancer Control · doi:10.1177/10732748251334434 · Cited by 9
Kato, K., Masuishi, T., Fushiki, K., Nakano, S., Kawamoto, Y., Narita, Y., Tsushima, T., Harada, K., Kadowaki, S., Todaka, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100179 · Cited by 9
Wissam, Y., Belcaid, L., Wittoek, R., Smith, V. M., Vanhaecke, A., Schepper, S. D., Jans, L. B. O., de Roodenbeke, D. '. K., Gombos, A., & Aspeslagh, S. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_8_19 · Cited by 9
Facing SARS-CoV-2 Outbreak in Immunotherapy Era
Citarella, F., Russano, M., Pantano, F., Dell’Aquila, E., Vincenzi, B., Tonini, G., & Santini, D. (2020) · Future Oncology · doi:10.2217/fon-2020-0340 · Cited by 9
Veccia, A., Sforza, V., Vattemi, E., Inno, A., Kinspergher, S., Dipasquale, M., Gori, S., Morabito, A., Baldi, I., & Caffo, O. (2021) · Immunotherapy · doi:10.2217/imt-2021-0002 · Cited by 9
Madonna, G., Masucci, G. V., Capone, M., Mallardo, D., Grimaldi, A. M., Simeone, E., Vanella, V., Festino, L., Palla, M., Scarpato, L., et al. (2021) · Cancers · doi:10.3390/cancers13164164 · Cited by 9
Self-citationKurzhals, J. K., Klee, G., Hagelstein, V., Zillikens, D., Terheyden, P. A. M., & Langan, E. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810723 · Cited by 9
Eosinophils in metastatic melanoma
Proffer, S. L., Guo, R., Demer, A. M., & Peters, M. S. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.08.001 · Cited by 9
Sibille, A., Henket, M., Corhay, J. L., Louis, R. E., & Duysinx, B. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1695063 · Cited by 9
Zhou, W., Zhou, Y., Cheng, Y., Shu, X., Wei, G.-X., Chen, X., Shen, X., & Qiu, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.749204 · Cited by 9
Edwards, J. M., Andrews, M. C., Burridge, H., Smith, R., Owens, C., Edinger, M., Pilkington, K. R., Desfrançois, J., Shackleton, M. J., Senthi, S., et al. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1466 · Cited by 8
Kim, S., & Sung, W. (2024) · Journal of Radiation Protection and Research · doi:10.14407/jrpr.2024.00017 · Cited by 8
Howard, H. R., Hasanova, M., Tiwari, A., Ghose, A., Winayak, R., Nahar, T. A. K., Chauhan, V., Arun, S. H., Palmer, K. R., Houston, A., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105557 · Cited by 8
Ascierto, P. A., Puzanov, I. J., Agarwala, S. S., Bifulco, C. B., Botti, G., Caracò, C., Ciliberto, G., Davies, M. A., Dummer, R., Ferrone, S., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1568-6 · Cited by 8
Self-citationNakamura, K., Ishiyama, Y., Nemoto, Y., Ishihara, H., Tachibana, H., Fukuda, H., Shinmura, H., Hashimoto, Y., Yoshida, K., Iizuka, J., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02341-x · Cited by 8
Non-Small Cell Lung Cancer – from Immunobiology to Immunotherapy
Bílek, O., Bohovicová, L., Demlová, R., Poprach, A., Lakomý, R., & Dubská, L. Z. (2016) · Klinicka onkologie · doi:10.14735/amko20164s78 · Cited by 8
Metadata
- Authors
- Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., Brenner, N., Kähler, K., Heinzerling, L., Gutzmer, R., Bender, A., Gebhardt, C., Romano, E., Meier, F., Martus, P., Maio, M., Blank, C., Schadendorf, D., Dummer, R., Ascierto, P. A., Hospers, G., Garbe, C., & Wolchok, J. D.
- Affiliations
- Universitätsklinikum Tübingen (DE)
- Heidelberg University (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Memorial Sloan Kettering Cancer Center (US)
- University Medical Center Groningen (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- 10Department of Dermatology, University of Zürich, Zürich, Switzerland.
- 12Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy.
- University Hospital Cologne (DE)
- University Hospital Schleswig-Holstein (DE)
- Universitätsklinikum Erlangen (DE)
- Medizinische Hochschule Hannover (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- German Cancer Research Center (DE)
- Institut Curie (FR)
- University of Tübingen (DE)
- University of Siena (IT)
- The Netherlands Cancer Institute (NL)
- University of Zurich (CH)
- Corresponding author
- Weide, Benjamin
- ORCID
- Weide, Benjamin
- Hassel, Jessica C.
- Berking, Carola
- Postow, Michael A.
- Bisschop, Kees
- Simeone, Ester
- Schilling, Bastian
- Brenner, Nicole
- Kähler, Katharina
- Heinzerling, Lucie
- Gutzmer, Ralf
- Gebhardt, Christoffer
- Romano, Emanuela
- Meier, Friedegund
- Martus, Peter
- Maio, Michele
- Blank, Christian
- Schadendorf, Dirk
- Dummer, Reinhard
- Ascierto, Paolo A.
- Hospers, Geke
- Garbe, Claus
- Wolchok, Jedd D.
- Venue
- Clinical Cancer Research
- Published
- 2016-11-14
- Volume
- 22
- Issue
- 22
- Pages
- 5487-5496
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC5572569
- OpenAlex
- W2397854274
- Semantic Scholar
- b5a9c4e2d6333e54d55ec140895bb53cebb851f9
- Cited by
- 589
- References
- 44
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 31 · 2023: 46 · 2022: 57 · 2021: 91 · 2020: 86 · 2019: 77 · 2018: 72 · 2017: 59 · 2016: 14
- FWCI
- 39.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, pembrolizumab, immune checkpoint blockade, prognostic factors, overall survival, lactate dehydrogenase, eosinophil count, lymphocyte count, metastasis, best overall response, predictive biomarkers
- MeSH terms
- Aged, Antibodies, Monoclonal, Female, Humans, L-Lactate Dehydrogenase, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Biomarkers, Tumor, Cohort Studies, Survival Analysis, Treatment Outcome, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
